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Sitamaquine is an 8-aminoquinoline which is active by the oral route for the treatment of life-threatening visceral leishmaniasis caused by
Leishmania donovani, with an IC50 of 29.2 μM against the promastigote form in vitro. At high concentration (100 μM), sitamaquine affected
parasite motility, morphology and growth in a way that was only partially reversible. As a first approach to determine its mechanism of action, we
describe the interaction of sitamaquine with parasite membrane components, representing the first barrier to be crossed by the drug. Analysis of
the physicochemical interactions of sitamaquine with monolayers of phospholipids and sterols at the air–water interface showed that these
interactions only occurred in the presence of anionic phospholipids. Thus, electrostatic interactions between positively charged sitamaquine and
the negative polar headgroups are a pre-requisite for subsequent hydrophobic interactions between the sitamaquine aromatic ring and the alkyl
chains of phospholipids leading to drug insertion into the monolayer.
© 2006 Elsevier B.V. All rights reserved.Keywords: Sitamaquine; Leishmania; Monolayer; Phospholipid1. Introduction
Leishmaniases are tropical and sub-tropical diseases caused
by protozoan parasites of the genus Leishmania. Three major
clinical expressions are found in humans, depending on the
Leishmania species involved: cutaneous, mucosal and visceral
leishmaniasis [1–3]. Despite efforts developed to find a vaccine
and to control the insect vector, chemotherapy remains the most
efficient way to overcome leishmaniasis. The treatment of
visceral leishmaniasis (VL) employs antimonials, drugs contain-
ing antimony, as the first-line treatment. In cases of antimonial
resistance, amphotericin B and its liposomal formulations are
used by the intravenous route. Recently, miltefosine (hexade-
cylphosphocholine or HePC), has been proposed for the
treatment of visceral leishmaniasis by the oral route [4].⁎ Corresponding author. Chimiothérapie Antiparasitaire UMR 8076 CNRS,
Faculté de Pharmacie, Université Paris XI, 5, rue Jean Baptiste Clément, 92296
Châtenay Malabry, France. Tel.: +33 1 46 83 55 55; fax: +33 1 46 83 55 57.
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doi:10.1016/j.bbamem.2006.07.003Sitamaquine (WR6026.2HCl), a 8-aminoquinoline, (Fig. 1) is
in clinical development for the treatment of visceral leishma-
niasis, also by the oral route [5–8]. Phase II trials in India and
Kenya were encouraging [9,10]. In order to assure a long life for
sitamaquine as anti-leishmanial drug, it is important to under-
stand its mechanism of action; however, the information
available remains fragmentary. Sitamaquine was described as
being responsible for an alteration of parasite morphology [11],
and the intracellular targets identified up to date are mitochon-
dria [12] and acidocalcisomes [13]. Whatever the mechanism,
sitamaquine has to cross the parasite membrane to reach its
biological targets. We hypothesize that sitamaquine, as a
cationic, amphiphilic molecule, could interact with membrane
lipids. In order to confirm this hypothesis, we have studied the
physico-chemical interactions between sitamaquine and lipid
monolayers, which serve as biomimetic models of external
monolayer of Leishmania plasma membrane.
In this paper, we describe the effect of sitamaquine on
Leishmania promastigotes and we analyze the specific
interactions of sitamaquine with the major lipid components
Fig. 1. Chemical structure of sitamaquine.
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of the charge of their polar head group and of their fluidity.
2. Materials et methods
2.1. Reagents
2.1.1. Sitamaquine
Sitamaquine [8-(6-diethylaminohexylamino)-6-methoxylepidine dihy-
drochloride], (WR6026.2HCl), is composed of two hydrophobic aromatic
rings and a hydrocarbon carbon chain, containing two positively charge
amine groups (Fig. 1). It was supplied by Glaxo Smith Kline (GSK, London,
UK, batch No 1003). Solutions of sitamaquine were prepared daily in
Millipore® water at an initial concentration of 10−3 M immediately before
monolayer experiments.
2.1.2. Lipids
The different lipids: 1,2-Dipalmitoyl-sn-glycero-3 phosphatidylglycerol
(DPPG), 1,2-Dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1,2-Dipal-
mitoyl-sn-glycero-3-phosphatidylinositol 4-monophosphate sodium salt extract
of brain (b4-PIP), 1,2-Dipalmitoyl-sn-glycero-3-phosphatidyl-myo-inositol-4-
monophosphate (DPPI-4P), 1,2-Distearoyl-sn-glycero-3-phosphatidylcholine
(DSPC), 1-Palmitoyl-2 oleoyl-sn-glycero-3-phosphatidylcholine (POPC), 1-
Palmitoyl-2 oleoyl-sn-glycero-3 phosphatidylethanolamine (POPE), cholesterol
and ergosterol were purchased from Sigma (Saint-Quentin Fallavier, France).
They were 99% pure, except for ergosterol (79% pure). These lipids were
dissolved in a chloroform/ethanol 4/1 (v/v) mixture at a concentration of
10−3 M. All organic solvents were HPLC quality and purchased from VWR,
(Strasbourg, France).2.2. Methods
2.2.1. Antileishmanial activity
2.2.1.1. Parasite strainsandculture. Promastigote forms of wild-type Leish-
mania donovani (MHOM/ET/67/HU3) clone were grown in M-199 medium
supplemented with 40 mM HEPES, 100 μM adenosine, 0.5 mg/l hemin, 10%
heat-inactivated foetal bovine serum (FBS) and 50 μg/ml gentamycin at 26 °C in
a dark environment. The experiments were performed with parasites in their
logarithmic phase.
2.2.1.2. IC50 determination on L. donovani promastigote forms in vitro [14].
The antileishmanial screening was performed in flat-bottomed 96-well plastic
tissue-culture plates maintained at 27 °C in an atmosphere of 95% air/5% CO2.
Promastigote forms from a logarithmic phase culture were suspended to yield
106 cells/ml after hemocytometer counting. Each well was filled with 100 μl of
the parasite suspension, and plates were incubated at 27 °C for 1 h before drug
addition. Sitamaquine solutions were added so as to attain the desired
concentrations of 100 μM and below; each in triplicate. After a 3-day
incubation period at 27 °C in the dark and under a 5% CO2 atmosphere, the
viability of promastigotes was assessed using the tetrazolium-dye, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide or MTT colorimetricmethod, which measures the reduction of a tetrazolium component (MTT) into
an insoluble formazan product by the mitochondria of viable cells. After
incubation of the cells with the MTT reagent, a detergent solution was added to
lyse the cells and dissolve the coloured crystals. The absorbance at 570 nm, was
directly proportional to the number of viable cells, was measured using an
ELISA plate reader. The results are expressed as the concentrations inhibiting
parasite growth by 50% (IC50) after a 3-day incubation period. HePC was used
as antileishmanial reference compound and was added in the same way as
sitamaquine.
2.2.1.3. Assessment of motility, morphology and growth. The effect sitama-
quine at 100 μM was observed microscopically by cell counting and
observation of morphology and motility as a function of the incubation time
(1, 3, 6, 24, 48 and 72 h) and of the fetal calf serum (FCS) concentration
within the medium (no serum, 10, 20 and 40%) in comparison with untreated
control cultures. After each incubation time, parasites were washed three
times in PBS and subcultured in drug-free M 199-medium for 72 h, after
which the capacity of the parasites to multiply was assessed by cell counting
in comparison with untreated controls.
2.2.2. Interaction of sitamaquine with phospholipids monolayers
Monolayers were prepared using a Teflon trough (6.2×26.3×0.5 cm)
provided by Riegler (Riegler and Kirstein, Wiesbaden, Germany filled with
Millipore® water (18 MΩ.cm, pH=5.6) as described elsewhere [15,16]. The
lipid monolayers were obtained by spreading 20 μl of a 10−3 M organic solution
of each lipid, at the air–water interface, except for DPPI-4P (50 μl of a 2×10−4
organic solution). The film was compressed 10 min after the evaporation of the
solvent, and the compression isotherms (P/A) was recorded.
The surface pressure (P) was measured using the Wilhelmy method, by
means of a filter paper plate [17]. The mean molecular area Awas determined as
A=S/N where S is the surface of the trough and N is the number of molecules
spread. An electronic device enabled us to keep the surface pressure constant by
monitoring the displacement of the barriers. The speed of movement of the
barriers (3×10−2 cm s−1) was kept constant during the experiments. All
experiments were performed at 21±1 °C.
The monolayer of phospholipid was compressed up to 30 mN/m (the surface
pressure of a biological membrane) [18,19]. This pressure was kept constant
while aqueous solutions of 10−3 M sitamaquine were injected with a
microsyringe under the monolayer at final concentrations of 0.2 to
3.5×10−5 M. If an interaction occurred between these molecules and the
monolayer, the barriers were moved back to keep the pressure at 30 mN/m and
the variation in the mean molecular area (ΔA) of the lipid was recorded as a
function of time over 60 min (adsorption kinetics). The molecules remaining at
the interface (lipids and any sitamaquine that had adsorbed and/or penetrated)
were compressed and a new P/A isotherm was recorded. If an interaction
(penetration and/or adsorption) of the drug with the monolayer had taken place,
this isotherm was shifted to higher area compared to the initial pure lipid
monolayer.
3. Results
3.1. Effect of sitamaquine on the parasites
3.1.1. Effect on parasite integrity, morphology and motility
The experiments were performed with an inoculum of
20×106 parasites/ml. This high parasite density allowed us to
observe changes in parasite morphology microscopically under
optimal conditions and to have sufficient parasites for
subsequent subcultures. Parasites were incubated in the
presence of 100 μM sitamaquine for 1, 3, 6, 24, 48 and 72 h,
after which they were counted. Fig. 2 shows the percentage of
parasite recovery as a percentage of untreated controls. After a
6-h incubation period, a large reduction of parasite number
(60%) was observed. Since this period is too short for parasite
multiplication, this decrease in parasite number can be ascribed
Fig. 2. In vitro effect of sitamaquine treatment on Leishmania donovani
promastigotes. Inoculum: 20×106 parasites/ml. Parasites were incubated in the
presence of sitamaquine (100 μM) for 1, 3, 6, 24, 48 or 72 h. They were counted
at the end of each incubation time, then washed and subcultured for a further
72 h before counting in comparison with control subcultures.
Table 1
Effect of a sitamaquine pretreatment at 100 μM on the IC50 of sitamaquine on
Leishmania donovani promastigotes subcultured in drug-free medium
Duration of sitamaquine pre-treatment IC50 (μM±SD) of sitamaquine
1 h 55.2±6.0
6 h 58.4±6.2
No treatment (control) 29.2±2.5
Fig. 3. Sitamaquine activity at 100 μM against L. donovani promastigotes as a
function of Fetal Calf Serum (FCS) concentration. Inoculum: 8×106 parasites/ml.
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numbers was observed from 24 to 72 h, resulting from growth
inhibition of the surviving parasites. Furthermore, the motility
of about 90% of the surviving parasites was severely affected
after 6 h of incubation. After a 24-h incubation period, most of
promastigotes exhibited rounded-up forms with reduced
motility, whereas untreated control parasites kept their slender
form and were motile. In summary, sitamaquine affects parasite
integrity, morphology and motility.
3.1.2. Reversibility of the sitamaquine effect
The reversibility of the action of sitamaquine on the
parasites was evaluated after exposure to 100 μM for
different periods of time. The treated parasites were washed
and subcultured in sitamaquine-free medium for a further
72 h. Fig. 2 shows that the subcultured parasites always had
a reduced capacity for multiplication compared to those that
had not been exposed to the drug before subculture.
Therefore, the action of sitamaquine was not reversible
since the inhibition of parasite multiplication persisted in
drug-free medium.
3.1.3. Dose dependence of the effect on parasite growth
The IC50 of sitamaquine against L. donovani promastigotes
was found at 29.2±2.5 μM after a 72-h incubation period.
The IC50 values for subcultures of parasites previously treated
with 100 μM sitamaquine for 1 h or 6 h were twice as high as
those of non treated parasites (58.4 and 29.2 μM, respec-
tively) indicating that the sensitivity of the parasites to
sitamaquine was significantly decreased after a first contact
(Table 1). Parasites incubated with 100 μM sitamaquine for
24, 48 and 72 h and washed were not able to multiply enough
to allow subsequent IC50 determination. These data confirm
the non reversibility of the effect of sitamaquine on parasite
growth.3.1.4. Serum effect on sitamaquine activity
The medium for promastigote culture usually contains 10%
fetal calf serum. However, sitamaquine could interact with
serum proteins. Therefore, we evaluated the effect of the serum
concentration in the medium on the antileishmanial effect of
sitamaquine, using an inoculum of 8×106 parasites/ml. Fig. 3
shows that sitamaquine activity was reduced as a function of the
serum concentration in the culture medium, suggesting that
sitamaquine, a positively charged molecule, probably interacts
with negative charges on plasma proteins.
In conclusion, we have observed that treatment of promas-
tigotes with n high concentration of sitamaquine (100 μM)
affected parasite integrity, morphology, motility and growth.
The lytic effect observed in the first hours of treatment could
be the result of a destabilizing drug–membrane interaction. In
addition, the electrostatic properties of sitamaquine could
explain its interaction with charged serum proteins. All these
observations prompted us to investigate whether sitamaquine
interacts with membrane lipids and particularly with negatively
charged phospholipids.
3.2. Monolayer results
Firstly, the tensioactive properties of sitamaquine alone were
studied at the air–water interface. The interactions of sitama-
quine with the principal lipids of plasma membrane of Leish-
mania donovani promastigotes were also investigated.
The choice of lipids used in this study was based on our
recently published results describing the nature of the polar head
groups and alkyl chains of phospholipids in plasma membranes
Fig. 5. Adsorption kinetics of sitamaquine injected under a DPPG monolayer
(ΔA versus time) at P=30mN/m. (subphase T=21±1 °C and pH=5.6).
Concentration of sitamaquine : (●) 0 μM, (□) 5 μM, (▪) 10 μM, (▴) 12 μM,
(○) 16 μM, (▾) 18 μM, (✖) 65 μM.
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are octadecanoic acid C18:0 (28%), 9-octadecenoic C18:1
(17%) and hexadecanoic C16:0 (11%). Head group determina-
tions indicated that the major polar lipids of surface membrane
from Leishmania are phosphatidylcholine PC (47%), phospha-
tidylethanolamine PE (26%), and phosphatidylinositol PI (7%).
The neutral lipids comprise mainly sterols (60%) and
diglycerides (30%), with some mannose and galactose-contain-
ing glycolipids [21–24].
3.2.1. Properties of sitamaquine alone
Different concentrations of sitamaquine were injected
directly in the aqueous subphase. No variation of the pressure
surface was obtained over 45 min, indicating that sitamaquine, a
soluble amphiphilic molecule, is not tensioactive.
3.2.2. Interaction of sitamaquine with phospholipids
3.2.2.1. Isotherms of phospholipids alone. The isotherms of
principal lipid components of the plasma membrane of Leish-
mania donovani promastigotes [20] recorded at 21±1 °C are
shown in Fig. 4. We observed that, at a pressure of 30 mN/m,
monolayers of ergosterol, DPPE, DPPG, DPPC and DPPI-4P
were in the liquid condensed (LC) and POPE, b4-PIP (extract
of brain) and POPC were in the liquid expanded (LE) states.
These results are consistent with those previously reported
[17,20,25–29]. The isotherms of DPPI-4P and b4-PIP were not
similar although the two phospholipids have the same polar
head with three negatives net charges. The difference is due to
the composition of alkyl chains: only saturated chains (2×C16)
for DPPI-4P and a mixture of saturated and unsaturated chains
for b4-PIP. Therefore, the fluidity of b4-PIP (LE phase) is
higher than DPPI-4P.Fig. 4. Isotherms of lipids and phospholipids at T=21±1 °C (subphase distilled
water at pH=5.6) (—) ergosterol, (□) DPPE, (▴) DPPG, (▪) DPPC, (○) DPPI-
4P, (✖) POPE, (▾) b4-PIP, (●) POPC.3.2.2.2. Role of the charge of the polar head group of
phospholipids on interactions with sitamaquine. Sitamaquine
was injected at different concentrations under zwitterionic
phospholipid (DSPC, DPPE, DPPC, POPE, and POPC),
anionic phospholipids (DPPG and b4-PIP) and sterol (ergos-
terol and cholesterol) monolayers. Its adsorption kinetics was
recorded over 45 min at 30 mN/m (ΔA versus time). The results
in the presence of DPPG are reported in Fig. 5. The area per
molecule increased rapidly to reach a maximum value
(ΔAmax). These values are plotted as a function of the
sitamaquine concentration in Fig. 6. The highest values of
ΔAmax observed in presence of anionic phospholipids (DPPG
and b4-PIP) were 21 and 25 Å2/molecule, respectively.
Generally the variation of the mean molecular area of
phospholipid monolayer obtained at high pressure (30 mN/m)
fall within a range of a few angstrom [15,16]. The high values
obtained suggest no only an adsorption but also an insertion of
sitamaquine into the monolayer of anionic phospholipids. The
concentration of drug which saturated DPPG and b4-PIP
monolayers respectively was 1.6×10−5 M and 1.2×10−5 M.
The difference of the net charge of these anionic phospholipids
could explain these results (one negative charge for DPPG andFig. 6. Maximum variation of the mean molecular area (ΔAmax) of DPPG (●)
and b4-PIP (▪), as a function of sitamaquine concentration injected under the
monolayer at P=30 mN/m. (subphase distilled water pH=5.6, T=21+1 °C).
Fig. 7. Compression isotherms (pressure versus area per molecule) for DPPG
and b4-PIP recorded before and after 45 min of sitamaquine adsorption
(C=1.6×10−5) at P=30 mN/m at T=21±1 °C. DPPG before (●) after (○), b4-
PIP (before (▪) and after (□).
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due to the presence of the polar heads of b4-PIP at the interface
is stronger than those induced by DPPG, therefore the b4-PIP
would have a stronger attractive effect on sitamaquine.
The values of ΔAmax reached in presence of the different
phospholipids are summarized in Table 2. The «zero» values
obtained in presence of zwitterionic and neutral phospholipids
monolayers indicate that no interaction with sitamaquine
occurred. furthermore, no direct interaction between sitama-
quine and sterols was detected.
The main result was that this cationic drug molecule only
interacted with the negatively phospholipids, presumably by
electrostatic interactions.
3.2.2.3. Effect of phospholipid fluidity. The data in Table 2
show that when interactions occur, the physical state of the
monolayer (condensed or expanded) influences the value of
ΔAmax. To investigate this, the following experiments were
performed: after 45 min adsorption of sitamaquine
(C=1.6×10−5) into monolayers of anionic phospholipid, the
monolayer was compressed again and, new isotherms were
recorded (Fig. 7). At high pressure (40 mN/m), a large shift of
the isotherm compared with that of the lipid alone indicated
that sitamaquine stays inserted into the lipid monolayer.
However, the ΔAmax obtained for b4-PIP (25 Å2/molecule)
was higher that that for DPPG (21 Å2/molecule) due to the
higher fluidity of b4-PIP (Fig. 4). Indeed, sitamaquine could
penetrate more easily into the monolayer of b4-PIP than into
those of DPPG. In order to study the fluidity parameter alone,
the adsorption kinetics with another anionic phospholipid,
DPPI4P (LC phase) were determined. Since DPPI-4P phos-
pholipid is very expensive, only one concentration of sitama-
quine (1.6×10−5 M) was studied. As shown in Table 2, the
maximal variation of mean molecular area (ΔAmax) value
depended on the fluidity of the lipid monolayer: 21 Å2/mol-
ecule in the presence of DPPI-4P and DPPG in the liquid
condensed phase and 25 Å2/molecule in the presence of b4PIP
in the liquid expanded phase, confirming that the insertion of
sitamaquine was favoured by fluid-phase phospholipids. These
results indicate that after electrostatic interaction, the aromaticTable 2
Interaction of sitamaquine with lipid monolayers at the air–water interface
(subphase: T=21±1 °C, pH=5.5, P=30 mN/m)
Lipid Net charge State of lipid
monolayer at
P=30 mN/m
ΔAmax
Å2/molec
Interaction
with
sitamaquine
ERGOSTEROL neutral condensed 0 no
CHOLESTEROL neutral condensed 0 no
DSPC zwitterionic condensed 0 no
DPPE zwitterionic condensed 0 no
DPPC zwitterionic condensed 0 no
DPPG anionic condensed 21 yes
DPPI-4P anionic condensed 21 yes
POPE zwitterionic fluid 0 no
b 4-PIP anionic fluid 25 yes
POPC zwitterionic fluid 0 nocycles of sitamaquine could penetrate between the phospho-
lipid alkyl chains by a hydrophobic effect.
4. Discussion
Sitamaquine is a 8-aminoquinoline in development as an
antileishmanial agent; however, little is known about its
mechanism of action. We report in this study that sitamaquine
has significant effects on Leishmania donovani morphology,
motility and growth. We chose a high concentration (100 μM)
in order to monitor significant biological effects more easily.
The change in parasite morphology could be the result of an
interference with proteins of the parasite cytoskeleton. The
rapid lysis observed could be ascribed, for example, to pore
formation within the plasma membrane leading to ion leakage
and osmotic stress. The absence of reversibility of the
sitamaquine action suggests severe damage to the target(s)
that cannot be corrected by the parasite. A previous study has
reported that sitamaquine provoked a fast and extensive
alkalization of Leishmania donovani acidocalcisomes, which
are acidic internal vacuoles containing sodium, calcium,
magnesium, zinc and phosphorus [12,13] . This indicates that
sitamaquine is able to cross the plasma membrane of the
parasite. Our present results showing that sitamaquine binds to
serum proteins suggest that it could probably also bind to
parasite membrane proteins. Since sitamaquine is a positively
charged and amphiphilic molecule, it could interact with both
negatively charged proteins and phospholipids at the level of the
membrane.
One aim of this study was to determine whether sitamaquine
might be able to enter the Leishmania cell independently of any
membrane transporter. We recently found that miltefosine
(hexadecylphosphocholine or HePC), another new antileishma-
nial drug, was able to interact with plasma membrane and enter
the parasite even in HePC-resistant parasites for which the
LdMT (Leishmania donovani Miltefosine Transporter) is
inactivated [20,30]. To date, no study has yet attempted to
identify a sitamaquine transporter; therefore we decided to
investigate the ability of sitamaquine to enter the parasite by
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model consisting of a monolayer of phospholipids, mimicking
the external face of the plasma membrane.
The first result obtained with the monolayers is that
sitamaquine has no tensioactive properties and therefore
cannot adsorb alone at the air/water interface. However, it
can interact directly with phospholipid spread at the air/water
interface. We have observed that these interactions occur only
between the positively charged sitamaquine and anionic
phospholipids, presumably by electrostatic interaction. Indeed,
the presence of anionic phospholipid PI and PG in plasma
membrane of WT parasites has been demonstrated in previous
work [21]. Moreover, in the first part of this study, it was
shown that activity of sitamaquine decreased in the presence
of FCS, possibly by interactions with negatively charged
proteins. This result argues for a high affinity of sitamaquine
for anionic molecules. These electrostatic interactions would
be a prerequisite for membrane–drug interaction.
The second important result is that, after the electrostatic
attraction, insertion of sitamaquine into a phospholipid mono-
layer occurs if the monolayer is in a fluid state. This association
increases with the fluidity of the monolayer and is probably due
to the insertion of the aromatic part of the sitamaquine between
the alkyl chains of the phospholipids. As it has been shown
previously that the plasma membranes of Leishmania donovani
promastigote are in the fluid state, this phenomenon could take
place in vivo. So, these results allow us to propose a mechanism
of sitamaquine insertion within the external monolayer of a
biological membrane by a two step-interaction: an electrostatic
interaction with negative head groups of phospholipids
followed by a hydrophobic interaction allowing a deeper
insertion of sitamaquine within the lipid monolayer. This
monolayer study allows us to understand how sitamaquine
could cross over the membrane. Thus, the following step will be
to study the passage of sitamaquine across a phospholipid
bilayer by using vesicles.
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